JP2024527362A5 - - Google Patents
Info
- Publication number
- JP2024527362A5 JP2024527362A5 JP2024500476A JP2024500476A JP2024527362A5 JP 2024527362 A5 JP2024527362 A5 JP 2024527362A5 JP 2024500476 A JP2024500476 A JP 2024500476A JP 2024500476 A JP2024500476 A JP 2024500476A JP 2024527362 A5 JP2024527362 A5 JP 2024527362A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligonucleotide
- sequence
- optionally
- complex according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220108P | 2021-07-09 | 2021-07-09 | |
| US63/220,108 | 2021-07-09 | ||
| PCT/US2022/073529 WO2023283615A1 (en) | 2021-07-09 | 2022-07-08 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527362A JP2024527362A (ja) | 2024-07-24 |
| JP2024527362A5 true JP2024527362A5 (enExample) | 2025-07-17 |
Family
ID=84802089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500476A Pending JP2024527362A (ja) | 2021-07-09 | 2022-07-08 | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240318177A1 (enExample) |
| EP (1) | EP4366783A4 (enExample) |
| JP (1) | JP2024527362A (enExample) |
| KR (1) | KR20240035826A (enExample) |
| CN (1) | CN118591391A (enExample) |
| AU (1) | AU2022306692A1 (enExample) |
| CA (1) | CA3226307A1 (enExample) |
| IL (1) | IL309935A (enExample) |
| MX (1) | MX2024000493A (enExample) |
| WO (1) | WO2023283615A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102775461B1 (ko) | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020219820A1 (en) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| NZ584793A (en) * | 2007-10-26 | 2012-05-25 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| AU2017364106A1 (en) * | 2016-11-28 | 2019-06-20 | The Board Of Regents Of The University Of Texas System | Prevention of muscular dystrophy by CRISPR/Cpfl-mediated gene editing |
| WO2020028832A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020219820A1 (en) * | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| CN120775052A (zh) * | 2019-10-10 | 2025-10-14 | 再凌生物医药(香港)有限公司 | 靶向bcma的具有人猴交叉的人源化单克隆抗体 |
| MX2023000984A (es) * | 2020-07-23 | 2023-05-03 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias. |
-
2022
- 2022-07-08 CN CN202280060812.8A patent/CN118591391A/zh active Pending
- 2022-07-08 CA CA3226307A patent/CA3226307A1/en active Pending
- 2022-07-08 JP JP2024500476A patent/JP2024527362A/ja active Pending
- 2022-07-08 WO PCT/US2022/073529 patent/WO2023283615A1/en not_active Ceased
- 2022-07-08 MX MX2024000493A patent/MX2024000493A/es unknown
- 2022-07-08 IL IL309935A patent/IL309935A/en unknown
- 2022-07-08 EP EP22838587.8A patent/EP4366783A4/en active Pending
- 2022-07-08 AU AU2022306692A patent/AU2022306692A1/en active Pending
- 2022-07-08 KR KR1020247004340A patent/KR20240035826A/ko active Pending
- 2022-07-08 US US18/577,378 patent/US20240318177A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024525611A5 (enExample) | ||
| JP2024525610A5 (enExample) | ||
| JP2024525613A5 (enExample) | ||
| JP2024525612A5 (enExample) | ||
| IL309935A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309937A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309911A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309912A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309909A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2023510350A5 (enExample) | ||
| JP2023535073A5 (enExample) | ||
| US20240325558A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| US20240117356A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| US20250099603A9 (en) | Muscle targeting complexes and uses thereof for treating friedreich's ataxia | |
| KR20240035825A (ko) | 디스트로핀병증을 치료하기 위한 근육 표적화 복합체 및 제제 | |
| JP2023509793A5 (enExample) | ||
| JP2024540199A5 (enExample) | ||
| JP2024540199A (ja) | ジストロフィノパチーを処置するための筋標的化複合体 | |
| JP2024524222A5 (enExample) | ||
| JP2024534488A5 (enExample) | ||
| RU2008149918A (ru) | Антитела к nkg2a и их применения | |
| JP2026503873A (ja) | Ｄｍｄ遺伝子のエクソン４５をスキップするための筋肉標的化複合体およびその使用 | |
| IL316206A (en) | Dosage of muscle targeting complexes for the treatment of myotonic dystrophy | |
| IL316143A (en) | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy | |
| JP2023549537A5 (enExample) |